Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dex-sparing regimens plus NEPA vs standard dexamethasone for prevention of CINV in cisplatin-treated NSCLC
2015-005704-29Phase 3Completed
- Sponsor
- Consorzio Oncotech
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of palonosetron and dexamethasone in chemotherapy-induced nausea and vomiting (CINV) and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Consorzio Oncotech. Primary endpoint: Complete response over 5-day overall period. Started Dec 2020; status: completed.
02
Drugs
palonosetrondexamethasone
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-005704-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005704-29.